Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Questcor Pharmaceuticals Inc. (QCOR - Analyst Report) provided an update on its portfolio at a Credit Suisse Healthcare conference.

Acthar, an injectable drug generated sales of $227.3 million in the third quarter of 2013. It is approved by the U.S. Food and Drug Administration (FDA) for as many as 19 indications. Strong performance of Acthar in the nephrotic syndrome (NS), systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis (MS) relapses and infantile spasms (IS) indications contributed to the substantial growth. 

Acthar is considered as the standard treatment for IS in children. As per Questcor, more than 100,000 MS relapses occur per year. According to Questcor, rheumatology represents the greatest market opportunity for Acthar. Rheumatology-related indications on the Acthar label include dermatomyositis/ polymyositis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Questcor has expanded the rheumatology sales force from 12 to 62.

Acthar is currently under evaluation for amyotrophic lateral sclerosis (ALS) (phase II), acute respiratory distress syndrome (phase II to begin shortly), diabetic nephropathy (phase II – enrolment expected to be completed in first half 2014), idiopathic membranous nephropathy (phase IV) and lupus (phase IV).

Questcor has acquired development and commercialization rights to Synacthen and Synacthen Depot from Novartis (NVS - Snapshot Report) in Jun 2013. This has led to the expansion of Questcor’s presence in the markets of inflammatory and autoimmune disorders.

Questcor carries a Zacks Rank #3 (Hold). Questcor’s growth going forward will be driven by increasing investment in research and development, developing international markets for Synacthen and Acthar and development of new indications. Currently, companies like Santarus, Inc. and Lannett Company, Inc. (LCI - Snapshot Report) look more attractive with a Zacks Rank #1 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%